Avalon GloboCare Overview
- Founded
- 2014
- Status
- Public
- Employees
- 8
- Stock Symbol
- AVCO
- Investments
- 5
- Share Price
- $1.14
- (As of Thursday Closing)
Avalon GloboCare General Information
Description
Avalon Globocare Corp is an intelligent biotech developer and healthcare service provider dedicated to promote and empower high impact, transformative biotechnology, and their clinical applications, and healthcare facility management. It has two reportable segments: real property operating segment which is the key revenue driver; medical-related consulting services segment; and development services and sales of developed products segment. The company focuses on the diagnostic and therapeutic areas like early detection of oral cancer, ovarian cancer, kidney cancer, skin regeneration and anti-fibrosis, and treatments of degenerative disorders.
Contact Information
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Stock Exchange
NAS
Primary Office
- 4400 Route 9 South
- Suite 3100
- Freehold, NJ 07728
- United States
+1 (732) 000-0000
Avalon GloboCare Timeline
Avalon GloboCare Stock Performance
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.14 | $1.21 | $0.50 - $2.19 | $98.5M | 81.4M | 380K | -$0.19 |
Avalon GloboCare Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2020 | FY 2019 31-Dec-2019 | FY 2018 31-Dec-2018 | FY 2017 31-Dec-2017 |
|---|---|---|---|---|
| EV | 102,302 | 144,242 | 197,289 | 169,790 |
| Revenue | 1,402 | 1,546 | 1,562 | 1,078 |
| EBITDA | (13,913) | (17,481) | (7,215) | (3,731) |
| Net Income | (15,028) | (18,070) | (7,774) | (3,464) |
| Total Assets | 11,156 | 10,491 | 13,396 | 12,669 |
| Total Debt | 3,450 | 3,190 | 1,000 | 1,500 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Avalon GloboCare Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
This information is available in the PitchBook Platform. To explore Avalon GloboCare‘s full profile, request access.
Request a free trialAvalon GloboCare Executive Team (5)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| David Jin Ph.D | Chief Executive Officer & Board Member | ||
| Luisa Ingargiola | Chief Financial Officer | ||
| Meng Li | Chief Operating Officer, Operations & Board Member |
Avalon GloboCare Board Members (5)
| Name | Representing | Role | Since |
|---|---|---|---|
| 00000 000 00.0 | Avalon GloboCare | Chief Executive Officer & Board Member | 000 0000 |
| 0000 00 | Avalon GloboCare | Chief Operating Officer, Operations & Board Member | 000 0000 |
| 000000 0000000 00 | Self | Board Member | 000 0000 |
| 0000000 000000 | Avalon GloboCare | Board Member | 000 0000 |
| 0000000 0000000 000 | Self | Board Member | 000 0000 |
Avalon GloboCare Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialAvalon GloboCare Investments & Acquisitions (5)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000000 000000000 | 23-Oct-2018 | 00000 0000000 | Drug Discovery | 00000 000 00.0 | |
| 000000 0000000 | 01-Sep-2018 | 00000 0000000 | Biotechnology | 00000 000 00.0 | |
| 0000000000 0000000 | 31-Oct-2017 | 000000000000000000 | 00.000 | Application Software | 00000 000 00.0 |
| 0000000 0000000 (0 | 25-Oct-2017 | 000000000000000000 | 00000 | Drug Discovery | 00000 000 00.0 |
| Freehold Executive Center | 05-May-2017 | Corporate Asset Purchase | 00.000 | Buildings and Property | 00000 000 00.0 |